191 related articles for article (PubMed ID: 21793074)
1. Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment.
Keshari KR; Tsachres H; Iman R; Delos Santos L; Tabatabai ZL; Shinohara K; Vigneron DB; Kurhanewicz J
NMR Biomed; 2011 Jul; 24(6):691-9. PubMed ID: 21793074
[TBL] [Abstract][Full Text] [Related]
2. Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy.
Swanson MG; Keshari KR; Tabatabai ZL; Simko JP; Shinohara K; Carroll PR; Zektzer AS; Kurhanewicz J
Magn Reson Med; 2008 Jul; 60(1):33-40. PubMed ID: 18581409
[TBL] [Abstract][Full Text] [Related]
3. The role of metabolic imaging in radiation therapy of prostate cancer.
Zhang VY; Westphalen A; Delos Santos L; Tabatabai ZL; Shinohara K; Vigneron DB; Kurhanewicz J
NMR Biomed; 2014 Jan; 27(1):100-11. PubMed ID: 23940096
[TBL] [Abstract][Full Text] [Related]
4. Metabolomic profiles of intact tissues reflect clinically relevant prostate cancer subtypes.
Dudka I; Lundquist K; Wikström P; Bergh A; Gröbner G
J Transl Med; 2023 Nov; 21(1):860. PubMed ID: 38012666
[TBL] [Abstract][Full Text] [Related]
5. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
Khatami A; Hugosson J; Wang W; Damber JE
Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
[TBL] [Abstract][Full Text] [Related]
6. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.
Tollefson MK; Karnes RJ; Kwon ED; Lohse CM; Rangel LJ; Mynderse LA; Cheville JC; Sebo TJ
Mayo Clin Proc; 2014 Mar; 89(3):308-18. PubMed ID: 24486077
[TBL] [Abstract][Full Text] [Related]
8. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
[TBL] [Abstract][Full Text] [Related]
9. Phosphorus magnetic resonance spectroscopic imaging at 7 T in patients with prostate cancer.
Lagemaat MW; Vos EK; Maas MC; Bitz AK; Orzada S; van Uden MJ; Kobus T; Heerschap A; Scheenen TW
Invest Radiol; 2014 May; 49(5):363-72. PubMed ID: 24335715
[TBL] [Abstract][Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
11. In vivo Metabolic Profiles as Determined by
Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
[TBL] [Abstract][Full Text] [Related]
12. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
Gettman MT; Pacelli A; Slezak J; Bergstralh EJ; Blute M; Zincke H; Bostwick DG
Urology; 1999 Sep; 54(3):479-85. PubMed ID: 10475358
[TBL] [Abstract][Full Text] [Related]
13. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues.
Swanson MG; Vigneron DB; Tabatabai ZL; Males RG; Schmitt L; Carroll PR; James JK; Hurd RE; Kurhanewicz J
Magn Reson Med; 2003 Nov; 50(5):944-54. PubMed ID: 14587005
[TBL] [Abstract][Full Text] [Related]
14. Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.
Tan N; Shen L; Khoshnoodi P; Alcalá HE; Yu W; Hsu W; Reiter RE; Lu DY; Raman SS
J Urol; 2018 May; 199(5):1218-1223. PubMed ID: 29128577
[TBL] [Abstract][Full Text] [Related]
15. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
Bettencourt MC; Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Moul JW
J Urol; 1996 Sep; 156(3):1064-8. PubMed ID: 8709308
[TBL] [Abstract][Full Text] [Related]
16. Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) tissue by 1H-NMR analysis: evidence for unusual phospholipid metabolism.
Teichert F; Verschoyle RD; Greaves P; Edwards RE; Teahan O; Jones DJ; Wilson ID; Farmer PB; Steward WP; Gant TW; Gescher AJ; Keun HC
Prostate; 2008 Jul; 68(10):1035-47. PubMed ID: 18459103
[TBL] [Abstract][Full Text] [Related]
17. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
18. 31P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia.
Komoroski RA; Holder JC; Pappas AA; Finkbeiner AE
Magn Reson Med; 2011 Apr; 65(4):911-3. PubMed ID: 20967792
[TBL] [Abstract][Full Text] [Related]
19. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy.
Aaltomaa S; Kärjä V; Lipponen P; Isotalo T; Kankkunen JP; Talja M; Mokka R
Anticancer Res; 2006; 26(6C):4873-8. PubMed ID: 17214354
[TBL] [Abstract][Full Text] [Related]
20. Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer.
Hegde JV; Chen MH; Mulkern RV; Fennessy FM; D'Amico AV; Tempany CM
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):e101-7. PubMed ID: 23040223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]